Independent briefing

Molecular residual disease across cancers, one sourced line at a time.

A daily briefing of sourced, fact-only updates on molecular residual disease, ctDNA, and MRD-relevant biomarkers across cancer types. Edited by Alan Tan, a genitourinary hematologist-oncologist. MRD and biomarker items are listed ahead of other news from the same stretch of days.

A free weekly MRD Watch email. No send date is set. Subscribe

Actively accruing studies How testing works

Edited by Alan Tan, MD

Latest Hematologic items. Open the Hematologic page.

How it works

A clear scan can still miss what is left

“No evidence of disease” means the scan did not show a tumor. Alan Tan, MD, puts the gap this way, as an illustration rather than a cutoff: “To the human eye, a clear scan can still hide around 200 million cancer cells.” MRD testing, especially ultrasensitive MRD, looks for that leftover signal in blood.

How testing works

Today

Nov 15, 2026 ET

No update is dated today. The latest verified items are below, with MRD and biomarker reports ranked first.

Leading updates

Pinned items, then MRD and biomarker reports, then newer dates.

Jan 21, 2026Heme MyelomaPinnedMRD / ctDNA FDA Guidelines

FDA draft guidance describes bone-marrow MRD negativity plus complete response as an accelerated-approval endpoint in myeloma

On January 21, 2026, the FDA released draft guidance on using minimal residual disease and complete response in multiple myeloma to support accelerated approval, defining the MRD endpoint as bone-marrow negativity by flow cytometry or sequencing in patients who have achieved complete response or stringent complete response, and noting that the April 12, 2024 ODAC unanimously accepted MRD as an accelerated-approval endpoint.

Federal Register

Recent

The leading list already holds every item on file.